HBME-1 IMMUNOSTAINING IN REACTIVE MESOTHELIAL CELLS VS. METASTATIC ADENOCARCINOMA IN SEROUS FLUIDS

被引：0
|
作者：
Moghaddam, N. Afshar
Zahedi, M. Dehghani
Rahmani, A.
Tahririan, R.
Heidarian, H.
机构：
[1] Isfahan Univ Med Sci, Fac Med, Dept Pathol, Esfahan, Iran
[2] Isfahan Univ Med Sci, Fac Med, Dept Gastroenterol, Esfahan, Iran
[3] Afshar Pathobiol Lab, Esfahan, Iran
[4] Bandar Abbas Univ Med Sci, Fac Med, Dept Pathol, Bandar Abbas, Iran
来源：
ACTA CYTOLOGICA | 2010年 / 54卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：472 / 472
页数：1
相关论文
共 50 条
  • [41] CARCINOMA-CELLS VERSUS REACTIVE MESOTHELIAL CELLS (RMC) IN BODY-FLUIDS - UTILITY OF IMMUNOPEROXIDASE STAINING FOR LEU-M1, B72.3, EMA, CEA, AND VIMENTIN
    TICKMAN, R
    COHEN, C
    VARMA, V
    FEKETE, P
    DEROSE, P
    LABORATORY INVESTIGATION, 1989, 60 (01) : A96 - A96
  • [42] A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion
    Yan, Jinhai
    Wei, Qingzhu
    Jian, Wenjing
    Liu, Jianghuan
    Tang, Hongping
    Ge, Juan
    Zhou, Jie
    Zhao, Tong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (09): : 5810 - 5818
  • [43] Studies on the role of Hypoxia-inducible factor HIF-1α in human Lung adenocarcinoma cells after Photon vs. Particle irradiation
    Kamlah, F.
    Bill, V
    Rudolph, S.
    Westholt, N.
    Fournier, C.
    Taucher-Scholz, G.
    Scholz, M.
    Kraft-Weyrather, W.
    Haenze, J.
    Arenz, A.
    Rose, F.
    Engenhart-Cabillic, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 137 - 137
  • [44] Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial)
    Ajani, Jaffer A.
    Abramov, Mikhail
    Bondar, Volodymyr
    Bondarenko, Igor
    Shparyk, Yaroslav V.
    Gorbunova, Vera
    Anatoliy, Hontsa
    Vinnyk, Yuriy
    Alsina, Maria
    Lazarev, Sergey
    Feliu, Jaime
    Elme, Anneli
    Esko, Vivian
    Rosati, Gerardo
    Abdalla, Kathia Cristina
    Verma, Udit N.
    Benedetti, Fabio M.
    Aoyama, Takekazu
    Mizuguchi, Hirokazu
    Makris, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates
    Wang, Luoquan
    Vuolo, Magalis
    Suhrland, Mark J.
    Schlesinger, Kathie
    ACTA CYTOLOGICA, 2006, 50 (03) : 257 - 262
  • [46] Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122)
    Frost, Nikolaj
    Bleckmann, Annalen
    Griesinger, Frank
    Grohe, Christian
    Janning, Melanie
    Kollmeier, Jens
    Reinmuth, Niels
    Sebastian, Martin
    Thomas, Michael
    Reck, Martin
    CLINICAL LUNG CANCER, 2023, 24 (06) : 568 - 572
  • [47] T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer
    Xue, Busheng
    von Heyking, Kristina
    Gassmann, Hendrik
    Poorebrahim, Mansour
    Thiede, Melanie
    Schober, Kilian
    Mautner, Josef
    Hauer, Julia
    Ruland, Juergen
    Busch, Dirk H.
    Thiel, Uwe
    Burdach, Stefan E. G.
    CANCERS, 2022, 14 (22)
  • [48] T CELLS DIRECTED AGAINST THE METASTATIC DRIVER CHONDROMODULIN-1 IN EWING SARCOMA: COMPARATIVE ENGINEERING WITH CRISPR/CAS9 VS. RETROVIRAL GENE TRANSFER FOR ADOPTIVE TRANSFER
    Thiel, Uwe
    von Heyking, Kristina
    Xue, Busheng
    Gassmann, Hendrik
    Thiede, Melanie
    Schober, Kilian
    Mautner, Josef
    Hauer, Julia
    Ruland, Juergen
    Busch, Dirk H.
    Burdach, Stefan E. G.
    BONE MARROW TRANSPLANTATION, 2024, 59 : 539 - 540
  • [49] The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).
    Renouf, Daniel John
    Kavan, Petr
    Dhani, Neesha C.
    Jonker, Derek J.
    Wei, Alice Chia-chi
    Hsu, Tina
    Tang, Patricia A.
    Graham, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Costs of generic vs. branded nab-paclitaxel (nP) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with gemcitabine plus nab-paclitaxel (GnP) in a real-world commercial database.
    Dennen, Syvart
    Masek, Marty
    Naga, Sai Sriteja Boppudi
    Cockrum, Paul
    Paluri, Ravi Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
12345